Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on antifibrotic therapy in inflammatory interstitial lung disease
ChiCTR2500105901Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pirfenidone and nintedanib in interstitial lung disease (ILD), organizing pneumonia (OP) and idiopathic nonspecific interstitial pneumonia (NSIP) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Forced Vital Capacity at 6 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
pirfenidonenintedanib
03
Conditions
interstitial lung disease (ILD)organizing pneumonia (OP)idiopathic nonspecific interstitial pneumonia (NSIP)
Beyond the preview
Go deeper on ChiCTR2500105901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105901.